Chris Marai's questions to Protagonist Therapeutics (PTGX) leadership • Q1 2020
Question
Chris Marai from Nomura Instinet asked for perspective on how PTG-300 would fit into daily clinical practice for polycythemia vera (PV), its potential placement in treatment lines relative to Jakafi, and any observed effects on spleen size.
Answer
Dr. Ronald Hoffman, Director of the Myeloproliferative Diseases Program at Mount Sinai, explained that PTG-300 could be a candidate for virtually all PV patients, both young and old. He sees it as an ideal treatment to avoid lifelong myelosuppressive therapy or as an adjunctive agent to eliminate the need for phlebotomies in patients on other treatments. Regarding spleen size, Dr. Hoffman noted that it's not a primary concern for most PV patients as they don't have symptomatic splenomegaly, and while animal models showed a reduction, the current human trial's sample size is too small to assess this endpoint.